Overview
Eugene John Vaios, MD, MBA, is an NIH-funded Assistant Professor of Radiation Oncology at the Duke Cancer Institute. He was previously at Harvard University where he completed his undergraduate and graduate education, as well as his internship at Cambridge Health Alliance. Eugene's research focus is at the intersection of radiation therapy and immunotherapy for patients with primary and metastatic brain tumors. Active translational research includes the development of a liquid biopsy for non-invasive diagnosis, surveillance, and prediction of treatment response in patients with brain tumors. Other interests include leveraging artificial intelligence and big data to improve cancer outcomes. Outside Duke, Eugene holds leadership positions on the ASTRO Board Finance and Audit Committee and serves on the Lancet Commission on Neurorehabilitation.
Current Duke Appointments & Affiliations
Recent News Items
View All News Items
Recent Scholarly Works
Identifying predictive factors for radiation necrosis vs local recurrence in biopsy-proven enlarging lesions post-stereotactic radiosurgery for brain metastases.
Journal article Neurooncol Pract · June 2026 BACKGROUND: Stereotactic radiosurgery (SRS) remains the standard of care for brain metastases (BM), offering effective local control with fewer neurocognitive side effects. However, distinguishing radiation necrosis (RN) from local recurrence (LR) is chall ... Full text Link to item CiteHuman Cytomegalovirus as a Therapeutic Target in Glioma Stem Cells.
Journal article Cells · March 24, 2026 Glioblastoma is the most aggressive tumor among gliomas, and recurrence remains inevitable despite aggressive therapies. Resistance to existing treatment modalities is attributed in part to the presence of glioma stem cells, which comprise a distinct cell ... Full text Link to item CiteComparison of Local Medicare Guidance and Medicare Advantage Plans for Stereotactic Radiosurgery for Brain Metastases.
Journal article Adv Radiat Oncol · February 2026 PURPOSE: Medicare Advantage operates under a capitated payment model, where Medicare Advantage Organizations (MAOs) must provide services that meet or exceed Medicare Parts A and B standards, ensuring actuarial equivalence. MAOs are mandated to base their ... Full text Link to item CiteRecent Grants
Elucidating Brain Tumor Biology and Response to Radiotherapy Using Cell-Free-DNA Methylation Signatures
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2027View All Grants